Ipafricept

Fusion Protein / Frizzled Receptor DecoyRx: InvestigationalCompound: Investigational

Also known as: Frizzled-8 Fc fusion protein, FZD8-Fc, OMP-54F28

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Ipafricept is an investigational Wnt pathway inhibitor developed by OncoMed Pharmaceuticals. It is a recombinant fusion protein (Frizzled-8/IgG1-Fc) that acts as a decoy receptor for Wnt ligands, blocking canonical Wnt/β-catenin signaling. It has been studied in Phase 1/2 clinical trials for various solid tumors including hepatocellular carcinoma, ovarian cancer, and pancreatic cancer, often in combination with chemotherapy or other targeted agents.

Mechanism of Action

Ipafricept (OMP-54F28) is a fusion protein combining the cysteine-rich domain of Frizzled-8 receptor with the Fc region of human IgG1. It acts as a Wnt pathway antagonist by sequestering Wnt ligands, thereby blocking Wnt/β-catenin signaling and inhibiting tumor cell proliferation and cancer stem cell renewal.

Routes of Administration

Intravenous

Goals & Uses

  • Ovarian cancer treatmentOncologyLow
  • Pancreatic cancer treatmentOncologyLow
  • Cancer stem cell targetingOncologyModerate
  • Hepatocellular carcinoma treatmentOncologyLow

Contraindications

  • Active pregnancyReproductive SafetyHigh
  • Severe hepatic impairmentOrganModerateLiver function concerns

Adverse Effects

  • DysgeusiaNeurologicalUncommon
  • NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
  • FatigueGeneralCommonLow energy or tiredness
  • Muscle-related toxicity (myalgia, muscle weakness)MusculoskeletalCommon
  • Decreased appetiteMetabolicCommonReduced desire to eat
  • Bone density loss / skeletal effectsMusculoskeletalUncommon

Drug Interactions

  • Paclitaxel / CarboplatinModerate
  • Nab-paclitaxel / GemcitabineModerate
  • SorafenibModerate

Population Constraints

  • Patients with pre-existing bone diseaseMusculoskeletalRelative
  • Pediatric patientsAgeRelative
  • Pregnant womenReproductiveAbsolute

Regulatory Status

  • European UnionInvestigationalNo EMA approval; investigational use only in clinical trial settings.
  • United StatesInvestigationalStudied under IND in Phase 1/2 clinical trials; no FDA approval. Development ongoing/paused by OncoMed/Celldex.
  • United KingdomInvestigationalNo MHRA approval; investigational only.

Not approved by any regulatory agency. Studied under IND in Phase 1/2 trials. Development has been primarily conducted by OncoMed Pharmaceuticals (now part of Celldex Therapeutics following acquisition activities).

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack